ENTRY       D11621            Mixture   Drug
NAME        Imipenem, cilastatin and relebactam;
            Relebactam hydrate, imipenem hydrate and cilastatin sodium;
            Recarbrio (TN)
PRODUCT     RECARBRIO (Merck Sharp & Dohme LLC)
COMPONENT   Imipenem [DR:D00206], Cilastatin sodium [DR:D02194], Relebactam [DR:D10726]
REMARK      Therapeutic category: 6129
            ATC code: J01DH56
            Product: D11621<JP/US>
EFFICACY    Antibacterial
  DISEASE   Uncomplicated urinary tract infection [DS:H01176]
TARGET      penicillin binding protein
            beta-lactamases
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J01 ANTIBACTERIALS FOR SYSTEMIC USE
               J01D OTHER BETA-LACTAM ANTIBACTERIALS
                J01DH Carbapenems
                 J01DH56 Imipenem, cilastatin and relebactam
                  D11621  Imipenem, cilastatin and relebactam &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antibacterials
              Carbapenems
               Imipenem/ Cilastatin/ Relebactam
                D11621  Imipenem, cilastatin and relebactam
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              61  Antibiotics
               612  Acting mainly on gram-negative bacteria
                6129  Others
                 D11621  Imipenem, cilastatin and relebactam
            Antimicrobials [BR:br08307]
             Antibacterials
              Cell wall biosynthesis inhibitor, beta-lactam
               Carbapenem
                D11621  Imipenem, cilastatin and relebactam &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11621
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11621
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11621
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11621
DBLINKS     PubChem: 405226488
///
